Report overview
The basic principle of chimeric antigen receptor T cell immunotherapy is to use the patient?s own immune cells to eliminate cancer cells. Among them, chimeric antigen receptor (CAR) is the core component of CAR-T, giving T cells HLA-independent recognition The ability of tumor antigens, which enables CAR-modified T cells to recognize a wider range of targets than the natural T cell surface receptor TCR. The basic design of CAR includes a tumor-associated antigen (TAA) binding region (usually derived from the scFV segment of the monoclonal antibody antigen binding region), an extracellular hinge region, a transmembrane region and an intracellular signal Area
This report aims to provide a comprehensive presentation of the global market for Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy. This report contains market size and forecasts of Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy in global, including the following market information:
Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Allogeneic CAR T-Cells Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy include Pfizer, Novartis, Bristol Myers Squibb, Legend Biotech, Sorrento Therapeutics, CARSGEN Therapeutics?Ltd, Juno Therapeutics, Kite Pharma and Atara Biotherapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Segment Percentages, by Type, 2022 (%)
Allogeneic CAR T-Cells
Autologous CAR T-Cells
Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Segment Percentages, by Application, 2022 (%)
Hospital
Diagnostic Center
Others
Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
Bristol Myers Squibb
Legend Biotech
Sorrento Therapeutics
CARSGEN Therapeutics?Ltd
Juno Therapeutics
Kite Pharma
Atara Biotherapeutics
Carina Biotech
Guangzhou Xiangxue Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy, market overview.
Chapter 2: Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
